Table 3. Clinical Outcome Rates on the Basis of Statin Therapy Intensity.

Variables		No-statin (n=59)	LMI (n=238)	HI (n=79)	HR (95% CI) No-stain vs. LMI	p value	HR (95% CI) No-stain vs. HI	p value
MACE		23 (39.0)	38 (16.0)	9 (11.4)	0.347 (0.206–0.583)	<0.001	0.256 (0.118–0.555)	0.001
	Death	20 (33.9)	29 (12.2)	7 (8.9)	0.309 (0.175–0.548)	<0.001	0.232 (0.098–0.550)	0.001
	MI	2 (3.4)	2 (0.8)	2 (2.5)	0.209 (0.029–1.491)	0.118	0.659 (0.093–4.697)	0.678
	Stroke	1 (1.7)	7 (2.9)	1 (1.3)	1.517 (0.185–12.414)	0.697	0.640 (0.040–10.261)	0.752
MALE		12 (20.9)	38 (16.0)	6 (7.6)	0.665 (0.338–1.308)	0.238	0.300 (0.111–0.812)	0.018
	TVR	9 (15.3)	32 (13.4)	6 (7.6)	0.690 (0.327–1.455)	0.330	0.372 (0.132–1.048)	0.061
	Major amputation	3 (5.1)	6 (2.5)	1 (1.2)	0.611 (0.123–3.032)	0.547	0.532 (0.143–3.421)	0.637

CI, confidence interval; HI, high-intensity; HR, hazard ratio; LMI, low-to-moderate intensity; MACE, major adverse cardiovascular events; MALE, major adverse limb events; MI, myocardial infarction; TVR, target vessel revascularization.

Data are presented as a n (%).